Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
29.3M
-
Shares change
-
-865K
-
Total reported value, excl. options
-
$285M
-
Value change
-
-$8.49M
-
Put/Call ratio
-
0.44
-
Number of buys
-
39
-
Number of sells
-
-33
-
Price
-
$9.69
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q2 2022
105 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q2 2022.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.3M shares
.
Largest 10 shareholders include BlackRock Inc. (3.54M shares), PICTET ASSET MANAGEMENT SA (3.53M shares), VANGUARD GROUP INC (2.93M shares), HHLR ADVISORS, LTD. (2.92M shares), BAKER BROS. ADVISORS LP (2.8M shares), Hudson Bay Capital Management LP (1.38M shares), GREAT POINT PARTNERS LLC (1.2M shares), ArrowMark Colorado Holdings LLC (1.15M shares), RICE HALL JAMES & ASSOCIATES, LLC (815K shares), and Opaleye Management Inc. (814K shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.